Recently, Huadao Biopharma, a cell therapy company in Zhangjiang Science City, completed a series C financing of nearly 200 million yuan. Sino Wisdom led the investment, and Kexing Equity Investment, YuHui Fund and Houlu Investment participated in the investment. This financing is Huadao Biopharma's another round of financing following the 100 million RMB Series B strategic financing in July 2019.

The financing will be mainly used for the construction and completion of the Phase I project of Huadao Biopharma’s Songjiang Base (HD CD19 CAR-T Injection Pilot Test Base + Cellular Immunotherapy Industrialization Technology Production Base) and the completion of HD CD19 CAR-T Injection Phase I Clinical Trials.

Huadao Biopharma was established in September 2017, focusing on the development of autologous CAR-T cell therapy products for hematoma and solid tumors and the independent innovation of the entire industrial chain of the cellular immunotherapy industry. In October 2019, its first cell drug variety CD19-CART cells was approved by the National CDE to conduct clinical trials. In addition, there are many CAR-T products under development.

At present, Huadao Biopharma's CAR-T cell product production whole industry chain production system covers all related processes such as engineering bacteria fermentation, plasmid purification, virus packaging, virus purification, T cell acquisition, T cell transfection, T cell amplification, harvesting and freezing. The development of an engineered production system for CAR lentiviral vectors that meets GMP standards has been completed, and the development of an engineered production system for CAR-T cell preparation with independent intellectual property rights is being further improved.